Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1890-1894

  Wu, Chun Ying ^a,b   Wu, Ming Shiang ^c   Chen, Yi Ju ^a   Chen, Hsiao Ping ^a   Chen, Chien Jen ^d   Chang, Chi Sen ^a   Lin, Jaw Town ^c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gastric cancer; Invasion; Single nucleotide polymorphism; Survival; uPA

Indexed keywords

PROUROKINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INTRON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH CANCER;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 57049091665     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Saksela O, Rifkin DB: Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 4:93-126.
2. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44:139-266.
3. Gyetko MR, Chen GH, McDonald RA, et al: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996; 97:1818-1826.
4. Myohanen H, Vaheri A: Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004; 61:2840-2858.
5. Blasi F: Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15:105-111.
6. Nekarda H, Siewert JR, Schmitt M, Ulm K: Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343:117.
7. Bacharach E, Itin A, Keshet E: In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992; 89:10686-10690.
8. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993; 90:5021-5025.
9. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14:297-307.
10. Nekarda H, Schmitt M, Ulm K, et al: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54:2900-2907.
11. Yonemura Y, Nojima N, Kaji M, et al: E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76:941-953.
12. Heiss MM, Babic R, Allgayer H, et al: Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13:2084-2093.
13. Herszenyi L, Plebani M, Carraro P, et al: Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 2000; 291:171-187.
14. Przybylowska K, Smolarczyk K, Kulig A, et al: Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer. Cancer Lett 2002; 181:23-30.
15. Yoshimoto M, Ushiyama Y, Sakai M, et al: Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. Biochim Biophys Acta 1996; 1293:83-89.
16. Conne B, Berczy M, Belin D: Detection of polymorphisms in the human urokinase-type plasminogen activator gene. Thromb Haemost 1997; 77:434-435.
17. Turkmen B, Schmitt M, Schmalfeldt B, et al: Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis 1997; 18:686-689.
18. Kocsis I, Gyorffy B, Nemeth E, Vasarhelyi B: Examination of Hardy-Weinberg equilibrium in papers of Kidney International: an underused tool. Kidney Int 2004; 65:1956-1958.
19. Hansen AP, Petros AM, Meadows RP, et al: Solution structure ofthe amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994; 33:4847-4864.
20. Li Y, Smith RA, Dobson CM: Sequential 1H NMR assignments and secondary structure of the kringle domain from urokinase. Biochemistry 1992; 31:9562-9571.
21. Gurewich V, Pannell R: Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69:769-772.